Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01694784
Other study ID # 12-1338
Secondary ID
Status Completed
Phase N/A
First received September 13, 2012
Last updated April 15, 2016
Start date September 2012
Est. completion date June 2014

Study information

Verified date April 2016
Source University of North Carolina, Chapel Hill
Contact n/a
Is FDA regulated No
Health authority United States: Federal GovernmentUnited States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Most prevention efforts focus on promoting services (e.g. vaccination, screening tests). While some of these services have clear net benefit, many instead have possible or clear net harm. Currently, three quarters of services graded by the U.S. Preventive Services Task Force (USPSTF) have possible or clear net harm (C, I, and D services). Many of these services are delivered in healthcare settings at higher rates than what might be expected based on their potential for harm. This leads to adverse outcomes, excess costs, and missed opportunities to deliver more quality care. An important issue in delivering prevention messages is how to shift toward a focus on the appropriateness of prevention: encouraging services with clear net benefit and either discouraging or reducing demand for services with possible or clear net harm. Unfortunately, little is known about what drives overuse of potentially harmful screening services or how to make harms relevant to patients.

This randomized controlled trial (RCT) of 775 patients at 4 primary care practices aims to 1) assess factors associated with intent to receive possibly or clearly harmful screening services and 2) determine whether and how patients' plans to get screened change with various presentations of information about harms (e.g. qualitative, quantitative, narrative, framed). The investigators will focus on three types of screening services: osteoporosis screening (previous C recommendation and now no recommendation for women < 65 years old with no fracture risk factors), prostate-specific antigen (PSA) screening (D recommendation for all men, regardless of age), and colorectal cancer (CRC) screening (C for ages 76-85).


Recruitment information / eligibility

Status Completed
Enrollment 775
Est. completion date June 2014
Est. primary completion date June 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 50 Years to 85 Years
Eligibility Inclusion Criteria:

- Women between ages 50 to 85

- Men between ages 50 to 85

- Eligible for exemplar service of interest (see below for specifics of inclusion/exclusion for specific services)

Exclusion Criteria:

- Current treatment of psychosis

- History of alcohol or substance abuse within the last 2 years

- Dementia or other severe cognitive dysfunction

- serious medical illnesses with a life expectancy of less than 2 years (e.g., metastatic cancer)

- inability to speak and understand English

- blindness

- presentation for an acute medical visit

- no telephone number

Osteoporosis Screening (women aged 50-64)

Exclusion Criteria:

- a personal history of osteoporosis

- a personal history of moderate or severe osteopenia

- BMI (body mass index) < 18.5

- personal history of non-traumatic fracture

- family history of hip fracture

- current smoking

- current use of prednisone (>30 consecutive days)

- alcohol use of 3 or more drinks/day.

Prostate Cancer screening (men aged 50-69)

Exclusion Criteria:

- a prior history of prostate cancer

Colorectal Cancer Screening (men and women aged 76-85)

Exclusion Criteria:

- prior history of colorectal cancer

- adenomatous colon polyps > 6mm (or 2 or more < 6mm)

- symptoms referable to colorectal cancer

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention


Intervention

Behavioral:
Quantitative Information Sheet
Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the quantitative information sheet, harms will be communicated in absolute risks with accompanying fact box (i.e. box containing key facts and rates). In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and the screening test, a description of the possible benefits of the service, and a statement encouraging decision. As an adjunct to numerical information in paragraph form, fact boxes engage individuals to process information and improve understanding.
Qualitative Information Sheet
Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the qualitative information sheet, harms will be communicated using verbal descriptors. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
Narrative Information Sheet
Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the narrative information sheet, harms will be communicated using patient narratives with accompanying fact box. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
Framed Information Sheet
Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the framed information sheet, harms will be communicated using a gain frame (as described in the arm section above) with accompanying fact box. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.

Locations

Country Name City State
United States Duke Primary Care Research Consortium Durham North Carolina

Sponsors (3)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill Agency for Healthcare Research and Quality (AHRQ), Duke University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Key moderating variables Multiple variables will be measured to examine whether they moderate the effect of the intervention on the primary outcome intent for screening.
These variables include:
self-efficacy for screening (1 question)
cues to action (6-questions on sources of health information)
perceived ambiguity of recommendations for screening (1 question)
personality traits (10-item personality index)
optimism (3 question subscale of life orientation test)
need for cognition (3 items from need for cognition scale)
health numeracy (3 items from Schwarz and Woloshin numeracy score)
prior screening status (1 item per service)
study site
health insurance status
pre-intervention No
Primary Change from Baseline in Intent to Accept Screening Immediately Post-intervention Following the example of others, we will measure intent to accept screening services with possible or clear net harm with a single item "I plan to get screened for (name of screening test) in the next year." Because the recommended screening intervals for services under study are variable and not all participants will be due for screening in the next year, we will additionally query participants about plans for screening within the recommended screening interval (e.g. osteoporosis screening--5 years; CRC--10 years). Responses will range from "strongly disagree" to strongly agree". All outcomes will be measured before and after participants receive the information sheet. All data will be collected at the one study visit. Pre and Post Intervention (same visit - Day 1) No
Secondary Change from Baseline in Perceived Disease Risk Immediately Post-Intervention Perceived risk or susceptibility of disease will be measured for each disease state under study using one item that reads, "How likely is that you will get (insert prostate cancer, osteoporosis, or colon cancer) in the next 10 years?" Answers will be on a likert scale from "not at all likely" to "very likely." Pre and Post Intervention (same visit - Day 1) No
Secondary Change from Baseline in Perceived Disease Severity Immediately Post-Intervention Perceived Disease Severity will be measured for each disease state under study using the Revised Illness Perceptions Questionnaire for Healthy People. It includes the following four questions: 1) x (insert prostate cancer, osteoporosis, or colon cancer) has serious financial consequences; 2) x strongly affects the way the patient sees himself as a person; 3) x causes difficulties to those close to the patient; 4) x is very serious. Answers will be on a 5-point scale from "strongly disagree" to "strongly agree." Pre and Post Intervention (same visit - Day 1) No
Secondary Change from Baseline in Disease Specific Knowledge Immediately Post-Intervention Two questions central to understanding each exemplar service (i.e. prostate cancer screening, osteoporosis screening, colon cancer screening) were selected to assess specific knowledge. Response options include true, false, or don't know.
Questions for prostate cancer screening are:
Some men can live long, normal lives with untreated prostate cancer.
Problems with sexual function and urination are common side effects of prostate cancer treatments.
Questions for colon cancer screening are:
Most polyps in the bowel never become cancer.
Bleeding and perforations are complications of a colonoscopy.
Questions for Osteoporosis screening are:
Broken hip bones are uncommon before age 65.
Treatments for osteoporosis can sometimes result in bone damage.
Pre and Post Intervention (same visit - Day 1) No
Secondary Change from Baseline in Disease-Specific Screening Attitudes Immediately Post-Intervention Six questions will assess participants' attitudes about each screening service under study.
Questions include:
Screening for x(insert prostate cancer, colon cancer, osteoporosis) in healthy persons my age is a good idea.
There is little harm to screening for x.
I owe it to people close to me to get screened for x.
I owe it to my doctor to get screened for x.
I would regret not being screened for x.
I do not feel any special responsibility to get screened for x.
Response options range from "strongly disagree" to "strongly agree".
Pre and Post Intervention (same visit - Day 1) No
Secondary Change from Baseline in Decisional Balance Immediately Post-Intervention Decisional balance will be measured by a single item for each screening service under study. Participants will be asked, "Which best describes how you feel right now?" Participants will select one of the following answers: 1) The benefits of X (insert prostate cancer, colon cancer, osteoporosis) screening greatly outweigh the harms; 2) The benefits of X screening somewhat outweigh the harms; 3) The benefits and harms of X screening are about the same; 4) The harms of X screening somewhat outweigh the benefits; and 5) The harms of X screening greatly outweigh the benefits. Pre and Post Intervention (same visit - Day 1) No
Secondary Change from Baseline in Values Clarity Immediately Post-Intervention Values Clarity will be measured with three items for the values subscale of the decisional conflict scale.
Items include:
I am clear about which benefits matter most to me;
I am clear about which harms and side effects matter most to me;
I am clear about which is more important to me (the benefits or the harms);
Response options range from strongly disagree to strongly agree.
Pre and Post Intervention (same visit - Day 1) No
Secondary Change from Baseline in General Screening Knowledge Immediately Post-Intervention General screening knowledge will be assessed using 8 items developed by investigators.
Questions include:
Screening means detecting disease before someone can see or feel any problem.
Some diseases detected by screening won't cause any problems in a person's lifetime.
In some cases, screening can lead to treatment that is not necessary.
Screening never harms anyone.
An abnormal screening test means I have the health condition for sure.
A normal screening test means that I have am free of the health condition for sure.
Screening can only decrease your chances of getting sick or dying if effective treatments are available.
Screening can only decrease your chances of getting sick or dying if you live long enough for treatments to work.
Response options are true, false, or don't know.
Pre and Post Intervention (same visit - Day 1) No
Secondary Change from Baseline in General Screening Attitudes Immediately Post-Intervention General Screening Attitudes will be assessed at baseline by 38 questions that were developed by investigators and assessed for content validity by panel of experts. Questions assess the following sub-constructs:
General approach to screening, Value of Screening, Need to Know about Disease, Early Detection/Treatment, Benefits, Harms, Anticipated Regret in Choosing for/against screening, Duty/Responsibility to be screened, Effect on screening on MD/patient relationship.
Response options range from "strongly disagree" to "strongly agree" on a 5-point scale.
At post intervention, a subset of 12 of the 38 questions (1-2 from each subconstruct) will be used to assess changes in general screening attitudes.
Pre and Post Intervention (same visit - Day 1)) No
See also
  Status Clinical Trial Phase
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A